Dbv technologies announces 2-year results from ongoing phase 3 open-label extension to the epitope trial (epopex) of viaskin™ peanut in toddlers

Montrouge, france, november 9, 2023 dbv technologies announces 2-year results from ongoing phase 3 open-label extension to the epitope trial (epopex) of viaskin™ peanut in toddlers viaskin peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
DBVT Ratings Summary
DBVT Quant Ranking